Related Experiment Video
Updated: Apr 17, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
HAART slows progression to anal cancer in HIV-infected MSM
Katrina C Duncan1, Keith J Chan, Connie G Chiu
1aBritish Columbia Centre for Excellence in HIV/AIDS, Faculty of Medicine, University of British Columbia bBritish Columbia Centre for Excellence in HIV/AIDS cDepartment of Surgery, St. Paul's Hospital dBritish Columbia Centre for Excellence in HIV/AIDS, Division of AIDS, University of British Columbia eBritish Columbia Cancer Agency, Vancouver fBritish Columbia Centre for Excellence in HIV/AIDS, Faculty of Health Sciences, Simon Fraser University, Burnaby gDivision of Infectious Diseases, University of British Columbia, Vancouver, British Columbia, Canada.
Objective:
Antiretrovirals do not prevent anal intraepithelial neoplasia. However, the influence of antiretrovirals in the natural history of invasive anal cancer is less clear. The objective is to investigate the impact of antiretrovirals in the time to the development of anal cancer in HIV-positive MSM.
Design:
A retrospective analysis of cases of anal cancer in a cohort of HIV-positive MSM receiving antiretrovirals between 1988 and 2008.
Methods:
Time from first CD4 cell count or HIV RNA viral load test to anal cancer diagnosis was analysed using Cox regression and Kaplan-Meier curves. Anal cancer cases treated in the era prior to HAART (<1996) were compared with those treated later (1996-2008).
Results:
Anal cancer cases (n = 37) were compared with a cohort of 1654 HIV-positive MSM on antiretrovirals. Antiretrovirals were started in the pre-HAART era by 70% of cancer cases, and median CD4 cell count nadir was 70 cells/μl (10-130). Time to development of anal cancer was shorter for cases treated during the pre-HAART era [adjusted hazard ratio (AHR) 3.04, 95% confidence interval (95% CI) 1.48-6.24, P = 0.002], with a CD4 cell count nadir less than 100 cells/μl (AHR 2.21, 95% CI 1.06-4.62, P = 0.035) and longer duration of CD4 cell count less than 100 cells/μl (AHR 1.33, 95% CI 1.11-1.58, P = 0.002).
Conclusion:
Results show that severe immunosuppression and starting therapy pre-HAART are associated with an increased risk of anal cancer. HIV-positive MSM initiating antiretrovirals during the HAART era (1996-2008) had a longer time to the development of anal cancer than those treated pre-HAART. Our results suggest that early use of HAART may delay progression to anal cancer.
Related Concept Videos
Retrovirus Life Cycles
Sexually Transmitted Infections
Tumor Progression
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression

